Responsibility Statement

To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements of the Merck Group give a true and fair view of the assets, liabilities, financial position and profit or loss of the Group, and the interim management report of the Group includes a fair review of the development and performance of the business and the position of the Group, together with a description of the principal opportunities and risks associated with the expected development of the Group for the remaining months of the financial year.

Darmstadt, May 15, 2012

Karl-Ludwig Kley

Kai Beckmann

Stefan Oschmann

Bernd Reckmann

Matthias Zachert

Interim Consolidated Financial Statements as of March 31, 2012

Consolidated Income Statement

€ million	Q1 – 2012	Q1 – 2011*
Sales	**2,563.9**	2,477.5
Royalty, license and commission income	81.1	86.2
Total revenues	**2,644.9**	**2,563.8**
Cost of sales	–748.7	–639.0
Gross profit	**1,896.2**	**1,924.8**
Marketing and selling expenses	–586.6	–590.0
Royalty, license and commission expenses	–120.0	–111.3
Administration expenses	–135.8	–129.9
Other operating expenses and income	–144.6	62.9
Research and development	–381.8	–378.8
Amortization of intangible assets	–216.3	–248.2
Investment result	–	–
Operating result (EBIT)	**311.2**	**529.5**
Financial result	–65.1	–68.3
Profit before income tax	**246.1**	**461.2**
Income tax	–69.4	–117.0
Profit after tax	**176.6**	**344.2**
of which attributable to Merck KGaA shareholders	174.2	341.1
of which non-controlling interest	2.4	3.1
Earnings per share (in €)		
basic	0.80	1.57
diluted	0.80	1.57

*Figures have been adjusted, see explanation on page 21.

Consolidated Statement of Comprehensive Income

€ million	Q1 – 2012	Q1 – 2011
Profit after tax	**176.6**	**344.2**
Available-for-sale financial assets		
Fair value adjustments	–	25.2
Reclassification to income statement	–	–4.4
Deferred taxes	–	0.8
Changes recognized in equity	**–**	**21.6**
Derivative financial instruments		
Fair value adjustments	25.6	11.8
Reclassification to income statement	42.0	2.1
Deferred taxes	–10.1	–0.6
Changes recognized in equity	**57.5**	**13.3**
Actuarial gains and losses from defined benefit obligations and similar obligations		
Changes in actuarial gains and losses	–1.0	–
Deferred taxes	–	–
Changes recognized in equity	**–1.0**	**–**
Exchange differences on translating foreign operations		
Changes taken directly to equity	–19.4	–69.1
Reclassification to income statement	–	3.5
Changes recognized in equity	**–19.4**	**–65.6**
Gains/losses recognized immediately in equity	**37.1**	**–30.7**
Comprehensive income	**213.8**	**313.5**
of which attributable to Merck KGaA shareholders	211.5	312.6
of which attributable to non-controlling interest	2.3	0.9

Consolidated Balance Sheet

€ million	March 31, 2012	Dec. 31, 2011
Current assets		
Cash and cash equivalents	1,086.8	937.8
Marketable securities and financial assets	755.2	1,117.1
Trade accounts receivable	2,343.5	2,328.3
Inventories	1,658.9	1,691.1
Other current assets	250.6	250.2
Tax receivables	67.8	72.7
	6,162.8	**6,397.2**
Non-current assets		
Intangible assets	11,466.7	11,764.3
Property, plant and equipment	3,020.9	3,113.4
Non-current financial assets	63.9	60.3
Other non-current assets	70.9	54.9
Deferred tax assets	705.1	730.0
	15,327.4	**15,722.9**
Total assets	**21,490.2**	**22,120.1**
Current liabilities		
Current financial liabilities	797.5	1,394.4
Trade accounts payable	1,112.8	1,100.8
Other current liabilities	1,101.7	1,102.1
Tax liabilities	364.2	399.4
Current provisions	360.0	365.5
	3,736.2	**4,362.2**
Non-current liabilities		
Non-current financial liabilities	4,061.9	4,144.9
Other non-current liabilities	16.5	43.6
Non-current provisions	623.4	619.5
Provisions for pensions and other post-employment benefits	1,143.6	1,136.9
Deferred tax liabilities	1,270.7	1,319.6
	7,116.2	**7,264.5**
Net equity		
Equity capital	565.2	565.2
Reserves	8,776.5	8,671.7
Gains/losses recognized immediately in equity	1,248.5	1,210.2
Equity attributable to Merck KGaA shareholders	**10,590.2**	**10,447.1**
Non-controlling interest	47.6	46.3
	10,637.8	**10,493.4**
Total liabilities and stockholders' equity	**21,490.2**	**22,120.1**

Consolidated Cash Flow Statement

€ million	Q1 – 2012	Q1 – 2011
Profit after tax	**176.6**	**344.2**
Depreciation/amortization/impairment losses/write-ups	342.7	353.0
Changes in inventories	7.0	–62.7
Changes in trade accounts receivable	–44.2	–30.6
Changes in trade accounts payable	26.1	–109.8
Changes in provisions	22.8	25.8
Changes in other assets and liabilities	–52.2	–68.2
Neutralization of gain/loss on disposals of assets	–10.1	–164.1
Other non-cash income and expenses	3.2	–2.6
Net cash flows from operating activities	**471.9**	**284.9**
Purchase of intangible assets	–29.1	–9.3
Purchase of property, plant and equipment	–50.7	–74.9
Acquisitions	–	–
Investments in financial assets	–5.6	–0.6
Disposal of non-current assets	31.4	485.4
Purchase/sale of marketable securities	1.7	–40.2
Changes in other financial assets	370.2	–256.1
Net cash flows from investing activities	**318.0**	**104.3**
Dividend payments	–0.7	–
Profit transfers to E. Merck KG and changes in reserves	–69.0	–104.8
Changes in liabilities to E. Merck KG	–10.0	–19.8
Repayment of bonds	–500.0	–
Changes in current and non-current financial liabilities	–58.2	–22.8
Net cash flows from financing activities	**–637.9**	**–147.4**
Changes in cash and cash equivalents	**152.0**	**241.8**
Changes in cash and cash equivalents due to currency translation	–3.0	–8.0
Cash and cash equivalents as of January 1 (Group balance sheet)	937.8	943.7
Plus cash and cash equivalents previously in assets held for sale	–	1.2
Cash and cash equivalents as of March 31	**1,086.8**	**1,178.7**

Consolidated Statement of Changes in Net Equity

	Equity capital		Reserves			Gains/losses recognized immediately in equity					
€ million	General partner's equity Merck KGaA	Subscribed capital Merck KGaA	Capital reserves (share premium) Merck KGaA	Retained earnings/Net retained profit	Actuarial gains and losses	Available-for-sale financial assets	Derivative financial instruments	Currency translation difference	Equity attributable to Merck KGaA shareholders	Non-controlling interest	Equity
Balance as of January 1, 2011	**397.2**	**168.0**	**3,813.7**	**5,040.9**	**–370.4**	**–3.1**	**–61.1**	**1,344.6**	**10,329.8**	**42.0**	**10,371.8**
Profit after tax	–	–	–	341.1	–	–	–	–	341.1	3.1	344.2
Gains/losses recognized immediately in equity	–	–	–	–	–	21.6	13.3	–63.4	–28.5	–2.2	–30.7
Comprehensive income	**–**	**–**	**–**	**341.1**	**–**	**21.6**	**13.3**	**–63.4**	**312.6**	**0.9**	**313.5**
Dividend payments	–	–	–	–	–	–	–	–	–	–	–
Profit transfers to/from E. Merck KG including transfers to reserves	–	–	–	–104.8	–	–	–	–	–104.8	–	–104.8
Changes in scope of consolidation/Other	–	–	–	–1.3	–0.1	–	–	–	–1.4	0.1	–1.3
Balance as of March 31, 2011	**397.2**	**168.0**	**3,813.7**	**5,275.9**	**–370.5**	**18.5**	**–47.8**	**1,281.2**	**10,536.1**	**43.0**	**10,579.1**
Balance as of January 1, 2012	**397.2**	**168.0**	**3,813.7**	**5,248.7**	**–390.7**	**0.8**	**–94.6**	**1,304.0**	**10,447.1**	**46.3**	**10,493.4**
Profit after tax	–	–	–	174.2	–	–	–	–	174.2	2.4	176.6
Gains/losses recognized immediately in equity	–	–	–	–	–1.0	–	57.5	–19.2	37.3	–0.2	37.1
Comprehensive income	**–**	**–**	**–**	**174.2**	**–1.0**	**–**	**57.5**	**–19.2**	**211.5**	**2.3**	**213.8**
Dividend payments	–	–	–	–	–	–	–	–	–	–0.7	–0.7
Profit transfers to/from E. Merck KG including transfers to reserves	–	–	–	–69.0	–	–	–	–	–69.0	–	–69.0
Changes in scope of consolidation/Other	–	–	–	0.6	–	–	–	–	0.6	–0.2	0.4
Balance as of March 31, 2012	**397.2**	**168.0**	**3,813.7**	**5,354.5**	**–391.7**	**0.8**	**–37.1**	**1,284.8**	**10,590.2**	**47.6**	**10,637.8**